InsidersTradesSigma
Total declarations
Company
▲ Purchases (0 ops.)
▼ Sales (3 ops.)
Insider track record
ExecutiveDisclosed buys
0
Disclosed sells
3
T+90 hit rate
0%
T+90 mean return
-21.5%
Across 8 buy signals with a settled T+90 return. Return basis: close on the day after publication.
Signal history
Explore the complete record of transactions filed by Taylor Ian, Directeur Scientifique. Insider active across 1 company, notably Arvinas, INC.. Aggregated, 16 reports have been logged. Breakdown: 0 buy · 3 sells. Total volume traded: €218k. Activity tracked since 16 August 2021. The latest transaction was disclosed on 24 February 2025 (Cession). Regulator: SEC (Form 4). All data is accessible without signup.
Declarations16 total
7,356 shares@ US$16.757.3% of flowCommon StockSEC:0001655759-25-000050:0
1,664 shares@ US$16.551.6% of flowCommon StockSEC:0001655759-25-000050:1
20,619 shares0Common StockSEC:0001655759-25-000025:0
39,250 shares0Common StockSEC:0001655759-24-000025:0
1,701 shares@ US$47.054.6% of flowCommon StockSEC:0001655759-24-000025:1
8,252 shares@ US$16.007.5% of flowCommon StockSEC:0001655759-24-000004:0
2,685 sharesCommon StockSEC:0001655759-23-000026:0
19,125 shares0Common StockSEC:0001655759-23-000017:0
3,000 shares0Common StockSEC:0001209191-22-022103:0
2,686 sharesCommon StockSEC:0001209191-22-016532:0
3,500 shares@ US$16.000.0066% mcap3.9% of flowCommon StockSEC:0001209191-22-016031:0
20,000 shares@ US$19.360.045% mcap26.8% of flowCommon StockSEC:0001209191-22-011074:0
12,206 shares@ US$16.000.022% mcap13.4% of flowCommon StockSEC:0001209191-21-065327:0
12,206 shares@ US$16.0010.6% of flowCommon StockSEC:0001209191-21-065327
20,000 shares@ US$16.000.036% mcap21.3% of flowCommon StockSEC:0001209191-21-052443:0
20,000 shares@ US$16.0016.8% of flowCommon StockSEC:0001209191-21-052443
16 of 16 declarations
About Taylor Ian
Ian Taylor is the Chief Scientific Officer at Arvinas, Inc. In this role, he is responsible for leading the company's research and development initiatives, focusing on innovation and advancement in therapeutic technologies. Ian plays a key role in Arvinas' scientific strategy, contributing to the company's mission of transforming disease treatment. His expertise in biotechnology is essential for the success of research projects.
